ATryn
antithrombin alfa
Table of contents
Overview
The marketing authorisation for Atryn has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
ATryn
|
| Agency product number |
EMEA/H/C/000587
|
| Active substance |
Antithrombin alfa
|
| International non-proprietary name (INN) or common name |
antithrombin alfa
|
| Therapeutic area (MeSH) |
Antithrombin III Deficiency
|
| Anatomical therapeutic chemical (ATC) code |
B01AB02
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Exceptional circumstances |
This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance. |
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Laboratoire Francais du Fractionnement et des Biotechnologies
|
| Revision |
16
|
| Date of issue of marketing authorisation valid throughout the European Union |
28/07/2006
|
| Contact address |
3 Avenue des Tropiques
ZA deCourtaboeuf 91940 Les Ulis France |
Product information
22/12/2018 ATryn - EMEA/H/C/000587 - IB/0038
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Antithrombotic agents
Therapeutic indication
ATryn is indicated for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency. ATryn is normally given in association with heparin or low molecular weight heparin.